Insulin soluble porcine 100units/ml solution for injection 3ml cartridges

Diabetes mellitus (DM) prevalence is rising worldwide. Current therapies comprising subcutaneous insulin injections can cause adverse effects such as lipodystrophy, local reactions like redness and swelling, fluid retention, and allergic reactions. Nanoparticle carriers for oral insulin are groundbreaking compared to existing methods because they are non-invasive treatments, showing operational convenience, controlled release profile, and ability to simulate the physiological delivery route into the bloodstream. These systems improve patient adherence and have demonstrated the potential to lower blood glucose levels in DM. We present a systematic review and meta-analysis aimed at compiling relevant data to pave the way for developing innovative nano- and microparticles for the oral delivery of insulin. Our analysis of 85 articles revealed that the diminution of glucose levels is not proportional to the administered insulin dosage, which ranged from 1 to 120 International Units (IU). The meta-analysis data indicated that 25 IU of encapsulated porcine insulin did not produce a statistically significant outcome (p = 0.93). In contrast, a dosage of 30 IU was efficacious in eliciting an optimal hypoglycemic effect compared to excipient controls. Parameters such as a high degree of encapsulation (~ 90%), particle size (200-400 nm), and polydispersity index (0.086-0.3) are all associated with lower blood glucose levels. These parameters were also significant in the linear regression analysis. Among the excipients employed, chitosan emerged as a prevalent excipient in formulations due to its biocompatible and biodegradable properties and its ability to establish stable polymeric matrices. Even though oral insulin administration is a promising therapeutic method, it cannot guarantee preclinical safety and therapeutic efficacy yet in regulating glucose levels in diabetic conditions.

Abstract licence: CC BY-NC-ND

Extracellular vesicles (EVs) facilitate intercellular communication and the conveyance of bioactive substances, including proteins, lipids, and nucleic acids. They play a significant role in various reproductive biological processes, including gametogenesis, fertilization, early embryo development, and implantation. Dysfunctional EV activity is associated with various reproductive diseases, such as polycystic ovary syndrome (PCOS), endometriosis, male infertility, and recurrent pregnancy loss (RPL). This review systematically examines and categorizes current knowledge on EV functions in reproductive biology and disorders, and their potential as diagnostic and therapeutic tools. A systematic literature search from 2000 to 2024 identified studies showing EVs' influence on gamete maturation, fertilization, embryonic development, and implantation. They also play a role in reproductive disorders by affecting insulin resistance, androgen production, inflammation, angiogenesis, sperm quality, and maternal-fetal immune tolerance. The review concludes that EVs are integral to reproductive health, with further research needed to understand their mechanisms and clinical potential.

Abstract licence: CC BY

Diabetes mellitus is characterised by an elevated blood glucose concentration. Over the last two decades, a plethora of new agents have emerged to help treat the condition, of which several classes of agent have been shown to reduce the risk of cardiovascular morbidity and mortality. In addition, there have been several developments in the pharmacology of insulin, improving the pharmacokinetics and pharmacodynamics of insulin analogues to better mimic physiological insulin concentrations in the liver, skeletal muscle, and other tissues. Furthermore, the technologies used to deliver insulin and measure glucose have improved; for example, in the UK, hybrid closed loop systems are now the standard of care for people with type 1 diabetes mellitus. This review focuses on insulin and insulin delivery. We consider the history of insulin development and the pharmacology of newer insulin analogues. We also describe the novel technologies available and the considerations that need to be made by anaesthetists, surgeons, and other members of the perioperative team when looking after someone with diabetes mellitus on these insulins, or using these devices, to ensure safe care and the avoidance of complications.

Abstract licence: CC BY